Dynorphin (2-17), Amide, Porcine Mechanisms, Clinical Applic

Dynorphin (2-17), Amide, Porcine: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Dynorphin (2-17), amide, porcine, is a synthetic peptide fragment derived from the endogenous opioid peptide dynorphin A. Dynorphins are a class of opioid peptides produced in the central nervous system (CNS) and peripheral tissues, primarily acting as ligands for the kappa-opioid receptor (KOR) (Chavkin et al., 1982, Science). The full-length dynorphin A (1-17) is cleaved in vivo to generate shorter, bioactive fragments such as dynorphin (2-17), which retain significant biological activity. The amide modification at the C-terminus enhances peptide stability and receptor affinity, making this analog a valuable tool for pharmacological and physiological studies (Wollemann & Benyhe, 2004, Pharmacol Ther).

Mechanistically, dynorphin (2-17), amide, porcine, exerts its effects primarily through activation of KORs, which are G protein-coupled receptors widely distributed in the CNS, including the spinal cord, hypothalamus, and limbic system. KOR activation modulates neurotransmitter release, inhibits adenylate cyclase activity, and regulates ion channel conductance, resulting in analgesic, anti-pruritic, and neuroprotective effects (Simonin et al., 1998, J Pharmacol Exp Ther). Importantly, dynorphin peptides also interact with non-opioid receptors, such as NMDA receptors, contributing to their complex pharmacological profile (Zhou et al., 2013, Neuropharmacology).

[Related: mog 35] Clinical Value and Applications
Dynorphin (2-17), amide, porcine, has emerged as a critical research tool for elucidating the physiological and pathological roles of dynorphin peptides in pain modulation, stress response, addiction, and neurodegeneration. Its selective KOR agonism makes it particularly valuable in preclinical models of pain and pruritus, where it has demonstrated potent antinociceptive and anti-itch effects (Inan & Cowan, 2004, Eur J Pharmacol).

In the context of pain management, dynorphin (2-17) offers a promising alternative to traditional mu-opioid receptor (MOR) agonists, such as morphine, which are associated with significant side effects including respiratory depression, tolerance, and addiction. KOR agonists like dynorphin (2-17) provide analgesia with a reduced risk of these adverse effects, making them attractive candidates for novel analgesic development (Bruchas et al., 2010, Trends Pharmacol Sci).

[Related: y-27632 dihydrochloride] Beyond pain, dynorphin (2-17) has been investigated for its role in modulating stress-induced behaviors, mood disorders, and neurodegenerative diseases. Preclinical studies suggest that KOR activation by dynorphin peptides can attenuate drug-seeking behavior and reduce relapse in models of substance use disorder (Shippenberg et al., 2007, Pharmacol Ther). Additionally, dynorphin fragments have shown neuroprotective effects in models of ischemic brain injury, possibly via modulation of excitotoxicity and inflammation (Hauser et al., 2005, J Neurochem).

Key Challenges and Pain Points Addressed
Current pharmacological approaches to pain and pruritus are limited by the side effect profiles of available agents. MOR agonists, while effective, are associated with high abuse potential and a range of adverse effects. Non-opioid analgesics, such as NSAIDs, are often insufficient for severe pain and carry risks of gastrointestinal and cardiovascular toxicity. There is a pressing need for new analgesics with improved safety and efficacy profiles.

[Related: z-devd-fmk] Dynorphin (2-17), amide, porcine, addresses several key challenges:
1. **Reduced Abuse Potential**: KOR agonists do not produce the euphoria associated with MOR agonists, lowering the risk of addiction.
2. **Alternative Analgesic Mechanism**: By targeting KORs, dynorphin (2-17) provides analgesia through distinct pathways, potentially benefiting patients unresponsive to conventional opioids.
3. **Anti-Pruritic Effects**: KOR agonists have demonstrated efficacy in reducing chronic itch, a symptom poorly managed by existing therapies (Bigliardi et al., 2009, J Invest Dermatol).
4. **Neuroprotection**: Dynorphin peptides may mitigate neuronal damage in neurodegenerative and ischemic conditions, offering a novel therapeutic avenue.

However, KOR agonists are not without challenges. Dysphoria, hallucinations, and sedation are notable side effects, and the precise balance between therapeutic and adverse effects remains an area of active investigation (Bruchas et al., 2010).

Literature Review
A growing body of literature supports the pharmacological and therapeutic relevance of dynorphin (2-17), amide, porcine, and related peptides:

1. **Chavkin et al. (1982, Science)**: This seminal study identified dynorphin as an endogenous ligand for KORs, establishing the foundation for subsequent research on dynorphin fragments.

2. **Simonin et al. (1998, J Pharmacol Exp Ther)**: The authors characterized the pharmacological profiles of dynorphin fragments, demonstrating that dynorphin (2-17) retains high affinity and selectivity for KORs.

3. **Inan & Cowan (2004, Eur J Pharmacol)**: This study evaluated the anti-pruritic effects of KOR agonists, including dynorphin analogs, in rodent models, highlighting their potential in treating chronic itch.

4. **Bruchas et al. (2010, Trends Pharmacol Sci)**: The review discusses the therapeutic potential and limitations of KOR agonists, emphasizing the need for selective ligands with favorable side effect profiles.

5. **Hauser et al. (2005, J Neurochem)**: The authors investigated the neuroprotective effects of dynorphin peptides in models of brain injury, suggesting a role in modulating excitotoxicity.

6. **Bigliardi et al. (2009, J Invest Dermatol)**: This clinical study demonstrated the efficacy of KOR agonists in reducing pruritus in patients with chronic skin disorders.

7. **Zhou et al. (2013, Neuropharmacology)**: The study explored the interaction of dynorphin fragments with NMDA receptors, providing insights into their complex pharmacology.

Collectively, these studies underscore the multifaceted roles of dynorphin (2-17), amide, porcine, in CNS function and disease.

Experimental Data and Results
Experimental studies have elucidated the pharmacodynamics and therapeutic potential of dynorphin (2-17), amide, porcine, in various preclinical models.

**Analgesic Efficacy**: In rodent models of acute and chronic pain, intrathecal administration of dynorphin (2-17) produced significant reductions in nociceptive responses, as measured by tail-flick and hot-plate assays (Simonin et al., 1998). The analgesic effects were dose-dependent and reversible by selective KOR antagonists, confirming receptor specificity.

**Anti-Pruritic Effects**: Inan & Cowan (2004) demonstrated that dynorphin (2-17) and other KOR agonists reduced scratching behavior in mice subjected to pruritogenic stimuli. The anti-pruritic effect was comparable to that of established KOR agonists, supporting its utility in itch management.

**Neuroprotection**: Hauser et al. (2005) reported that dynorphin (2-17) administration in models of cerebral ischemia reduced neuronal death and improved functional outcomes. The neuroprotective effect was attributed to modulation of glutamate release and attenuation of excitotoxicity.

**Behavioral Effects**: While KOR agonists are associated with dysphoric and sedative effects, studies indicate that dynorphin (2-17) exhibits a favorable side effect profile at therapeutic doses, with minimal impact on locomotor activity and mood in animal models (Bruchas et al., 2010).

**Receptor Binding**: Radioligand binding assays confirm that dynorphin (2-17), amide, porcine, exhibits high affinity for KORs, with negligible activity at MORs and delta-opioid receptors (DORs), supporting its selectivity (Simonin et al., 1998).

Usage Guidelines and Best Practices
Dynorphin (2-17), amide, porcine, is primarily utilized as a research reagent in preclinical studies. The following guidelines are recommended for its effective and safe use:

1. **Preparation and Storage**: The peptide should be reconstituted in sterile water or physiological saline, with aliquots stored at -20°C to maintain stability. Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 31 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11569199